Project Grant R21CA303380
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $640,597 to the University of California, Los Angeles, effective June 1, 2026 through May 31, 2031, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The research program develops and validates amine chemical exchange saturation transfer echo-planar imaging (CEST-EPI), a pH-sensitive magnetic resonance imaging technique designed to enable high-resolution visualization of...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The primary deliverable is the first-in-man clinical imaging study of [77Br]Br-WC-DZ, a bromine-77 ligand targeting...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $402,401.00 to Emory University to develop a PET CCR2 imaging agent to profile the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC). The project aims to advance diagnostic and profiling capabilities for this highly aggressive cancer, which is the 4th leading cause of cancer-related death. The award has a period of performance from July 4, 2024 to...
- Federal Project Grant Award Summary The University of Pittsburgh received a $435,788 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This award supports the development of active site-directed inhibitors and bifunctional degraders targeting mutant isocitrate dehydrogenase (IDH1 and IDH2) enzymes implicated in progressive gliomas and hematological malignancies. The research addresses a...
- Federal Project Grant Award Summary Northern Michigan University received a $462,153 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on September 4, 2025, with a completion date of August 31, 2026. The award supports the development and application of D2HGLO, a novel genetically encoded fluorescent biosensor tool designed to detect and quantify the oncometabolite D-2-hydroxyglutarate (D-2-HG) in intact cells. This biosensor addresses...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia State University Research Foundation Inc. a $406,258 Project Grant on July 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop novel covalent anti-cancer drugs utilizing phosphorus fluoride exchange (PFEX) click chemistry. The two-year research initiative, concluding June 30, 2027, focuses on designing privileged covalent warheads with expanded target scopes to overcome limitations of...
- Federal Grant Award Summary Emory University received a $572,378 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. The award supports fundamental research investigating metabolic gatekeeping mechanisms that regulate dormancy in disseminated non-small cell lung cancer (NSCLC) subpopulations. The research employs image-guided genomics approaches to examine how collective invasion...
- Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...
Emory University received a $402,401 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective May 6, 2026, with a completion date of April 30, 2028. The award supports the development of an 18F-labeled positron emission tomography (PET) imaging agent capable of detecting and measuring isocitrate dehydrogenase 1 mutant (IDH1-R132H) expression in gliomas. This exploratory research project involves synthesizing six rationally designed heteroaromatic analogs of AG-881, an IDH1-R132H inhibitor currently in clinical trials, and evaluating their inhibitory properties in glioma cell cultures. The research team will subsequently develop and optimize an 18F-radiolabeling approach for the most promising candidates to create a mutation-specific PET tracer. The project directly addresses a critical diagnostic gap in the clinical management of low-grade gliomas and secondary glioblastoma multiforme, where IDH1 mutations are present in over 70 percent of cases. By developing a non-invasive imaging methodology to detect mutational status, this research will enable improved clinical diagnosis, patient stratification, and monitoring of drug-target engagement for emerging IDH1-targeted therapies, thereby reducing the need for repeated tissue biopsies and supporting ongoing clinical trials of IDH inhibitor treatments.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $402.4k | 5/7/26 |